Skip to content
10-K

Annual Report

Lantern Pharma Inc. LTRN

0001493152-26-013612

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 13, 2026 11.25M sh
Shares Diluted FY 2025 · Dec 31, 2025 10.9M sh
Shares Diluted FY 2025 · Dec 31, 2024 10.76M sh
Capex FY 2025 · Dec 31, 2025 $1.72K
Capex FY 2025 · Dec 31, 2024 $12.6K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$15.68M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$17.81M
Cash And Equivalents FY 2025 · Dec 31, 2025 $4.42M
Cash And Equivalents FY 2025 · Dec 31, 2024 $7.51M
Stockholders Equity FY 2025 · Dec 31, 2025 $6.53M
Stockholders Equity FY 2025 · Dec 31, 2024 $21.19M
Stockholders Equity FY 2025 · Dec 31, 2023 $40.91M
Current Liabilities FY 2025 · Dec 31, 2025 $4.5M
Current Liabilities FY 2025 · Dec 31, 2024 $4.33M
Total Liabilities FY 2025 · Dec 31, 2025 $4.5M
Total Liabilities FY 2025 · Dec 31, 2024 $4.38M
Current Assets FY 2025 · Dec 31, 2025 $10.8M
Current Assets FY 2025 · Dec 31, 2024 $25.25M
Total Assets FY 2025 · Dec 31, 2025 $11.04M
Total Assets FY 2025 · Dec 31, 2024 $25.57M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.57
Eps Diluted FY 2025 · Dec 31, 2024 −$1.93
Eps Basic FY 2025 · Dec 31, 2025 −$1.57
Eps Basic FY 2025 · Dec 31, 2024 −$1.93
Sga Expense FY 2025 · Dec 31, 2025 $6.46M
Sga Expense FY 2025 · Dec 31, 2024 $6.09M
Rd Expense FY 2025 · Dec 31, 2025 $11.51M
Rd Expense FY 2025 · Dec 31, 2024 $16.13M
Net Income FY 2025 · Dec 31, 2025 −$17.12M
Net Income FY 2025 · Dec 31, 2024 −$20.78M
Operating Income FY 2025 · Dec 31, 2025 −$17.98M
Operating Income FY 2025 · Dec 31, 2024 −$22.22M